Antibiotics and beyond: Unraveling the dynamics of bronchopulmonary dysplasia in very preterm infants

Marina P. Menegolla,Rita C. Silveira,Antônio R H Görgen,Fernanda E. Gandolfi,Renato S. Procianoy
DOI: https://doi.org/10.1002/ppul.27182
IF: 4.0899
2024-07-20
Pediatric Pulmonology
Abstract:Background Bronchopulmonary dysplasia (BPD) remains a significant challenge in neonatal care. Prenatal inflammation and neonatal sepsis contribute to the multifactorial nature of BPD. A potential association between empirical antibiotic therapy and BPD risk has been proposed due to microbiota dysbiosis in very low birth weight premature infants. Methods A single centered retrospective cohort study of preterm infants (24–32 weeks gestation) from 2014 to 2021. The study compared groups that received empirical antibiotics in the first days of life and those that did not receive any antibiotic in the first days of life. The primary outcomes studied were BPD, death, and the combined outcome of BPD/death. Statistical analysis employed t‐tests, Mann‐Whitney U, Chi‐square, and logistic regression. Results Of 454 preterm infants, 61.5% received antibiotics. This group had lower gestational age, birth weight, and Apgar scores. Antibiotic use was associated with higher incidence of BPD (35.5% vs. 10.3%), death (21.5% vs. 8.6%), and combined outcomes (54.5% vs. 18.3%). In multivariate analysis, antibiotic use independently associated with BPD (OR 2.58, p
pediatrics,respiratory system
What problem does this paper attempt to address?